Capricor Therapeutics (CAPR) News Today $13.07 +0.17 (+1.32%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 14.5% in NovemberCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 4,410,000 shares, an increase of 14.5% from the November 15th total of 3,850,000 shares. Based on an average trading volume of 3,430,000 shares, the short-interest ratio is presently 1.3 days.December 16, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Stock Price Down 5.3% - Time to Sell?Capricor Therapeutics (NASDAQ:CAPR) Shares Down 5.3% - Time to Sell?December 13, 2024 | marketbeat.com250,204 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Point72 Asset Management L.P.Point72 Asset Management L.P. bought a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 250,204 shares of the biotechnology company's stock, valued at approDecember 9, 2024 | marketbeat.comDeramiocel's Promise Brightens Capricor's Outlook, With Strings AttachedDecember 7, 2024 | seekingalpha.comCapricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA SubmissionDecember 6, 2024 | seekingalpha.comCapricor unlikely impacted by Phan warning letter, says JonesResearchDecember 6, 2024 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)December 3, 2024 | markets.businessinsider.comCapricor Therapeutics to Present at Upcoming Investor ConferencesDecember 2, 2024 | globenewswire.comCapricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Rating of "Buy" from AnalystsCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price targetDecember 1, 2024 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Short Interest UpdateCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 3,850,000 shares, a decline of 27.1% from the October 31st total of 5,280,000 shares. Based on an average trading volume of 3,160,000 shares, the short-interest ratio is currently 1.2 days.November 30, 2024 | marketbeat.comOppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)November 21, 2024 | markets.businessinsider.comCapricor Therapeutics granted ODD, ATMP status for deramiocel by EMANovember 20, 2024 | markets.businessinsider.comCapricor wins key EU designations for the lead assetNovember 20, 2024 | msn.comCapricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines AgencyNovember 20, 2024 | markets.businessinsider.comJones Trading Initiates Coverage of Capricor Therapeutics (CAPR) with Buy RecommendationNovember 18, 2024 | msn.comCapricor Therapeutics initiated with a Buy at JonesResearchNovember 18, 2024 | markets.businessinsider.comStrong Buy Rating for Capricor Therapeutics Driven by Deramiocel’s Promising Potential in DMD Treatment and Strategic PartnershipsNovember 18, 2024 | markets.businessinsider.comHC Wainwright Brokers Increase Earnings Estimates for CAPRCapricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - HC Wainwright increased their FY2024 EPS estimates for shares of Capricor Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per shNovember 18, 2024 | marketbeat.comCapricor Therapeutics Third Quarter 2024 Earnings: Misses ExpectationsNovember 16, 2024 | finance.yahoo.comCapricor Therapeutics: Promising Developments and Strong Financial Position Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comIs Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?November 16, 2024 | msn.comQ3 2024 Capricor Therapeutics Inc Earnings CallNovember 15, 2024 | finance.yahoo.comCapricor Therapeutics Advances with Strategic ExpansionsNovember 15, 2024 | markets.businessinsider.comCapricor Therapeutics: Strategic Positioning and Financial Stability Drive Buy RatingNovember 15, 2024 | markets.businessinsider.comCapricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher After Analyst UpgradeCapricor Therapeutics (NASDAQ:CAPR) Stock Price Up 7.3% After Analyst UpgradeNovember 14, 2024 | marketbeat.comCantor Fitzgerald Boosts Capricor Therapeutics (NASDAQ:CAPR) Price Target to $30.00Cantor Fitzgerald lifted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday.November 14, 2024 | marketbeat.comCapricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comCapricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | globenewswire.comCapricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual MeetingNovember 12, 2024 | markets.businessinsider.comOppenheimer Sticks to Their Buy Rating for SAB Biotherapeutics (SABS)November 9, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Catalyst Pharma (CPRX)November 9, 2024 | markets.businessinsider.comCapricor Therapeutics (NASDAQ:CAPR) Stock Price Up 10.6% - What's Next?Capricor Therapeutics (NASDAQ:CAPR) Shares Up 10.6% - Still a Buy?November 7, 2024 | marketbeat.comCapricor Therapeutics (CAPR) Scheduled to Post Earnings on WednesdayCapricor Therapeutics (NASDAQ:CAPR) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 6, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Stock Price Crosses Above Fifty Day Moving Average - What's Next?Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving Average - Time to Sell?November 6, 2024 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Recommendation of "Buy" from BrokeragesShares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have received an average rating of "Buy" from the six brokerages that are covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts thNovember 6, 2024 | marketbeat.comCapricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13November 5, 2024 | markets.businessinsider.comAlnylam Pharma (ALNY) Receives a Hold from OppenheimerNovember 1, 2024 | markets.businessinsider.comBrainstorm Cell Therapeutics (BCLI) Receives a Buy from Maxim GroupOctober 31, 2024 | markets.businessinsider.comIterum Therapeutics (ITRM) Receives a Buy from Maxim GroupOctober 30, 2024 | markets.businessinsider.comCapricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 17.9% in OctoberCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 6,180,000 shares, a growth of 17.9% from the September 30th total of 5,240,000 shares. Based on an average daily volume of 2,880,000 shares, the days-to-cover ratio is currently 2.1 days.October 29, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Trading Down 3.3% - Should You Sell?Capricor Therapeutics (NASDAQ:CAPR) Trading Down 3.3% - Should You Sell?October 28, 2024 | marketbeat.comCapricor Therapeutics Options Trading: A Deep Dive into Market SentimentOctober 24, 2024 | benzinga.comPiper Sandler Initiates Coverage of Capricor Therapeutics (CAPR) with Overweight RecommendationOctober 22, 2024 | msn.comCapricor Therapeutics initiated with an Overweight at Piper SandlerOctober 22, 2024 | markets.businessinsider.comBuy Rating for Capricor Therapeutics: Promising Deramiocel Development and Strategic PartnershipsOctober 22, 2024 | markets.businessinsider.comCapricor Therapeutics files to sell 2.8M shares of common stock for holdersOctober 22, 2024 | msn.comCapricor Therapeutics (NASDAQ:CAPR) Trading Up 4.3% - Here's WhyCapricor Therapeutics (NASDAQ:CAPR) Shares Up 4.3% - What's Next?October 21, 2024 | marketbeat.comCapricor Therapeutics initiated at Overweight by Piper SandlerOctober 21, 2024 | msn.comPiper Sandler Begins Coverage on Capricor Therapeutics (NASDAQ:CAPR)Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday. They issued an "overweight" rating and a $35.00 price target on the stock.October 21, 2024 | marketbeat.comCapricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesOctober 20, 2024 | finance.yahoo.com Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW CAPR Media Mentions By Week CAPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CAPR News Sentiment▼1.940.60▲Average Medical News Sentiment CAPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CAPR Articles This Week▼14▲CAPR Articles Average Week Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CPRX News Today AGIO News Today PTGX News Today AMRX News Today LBPH News Today LGND News Today GERN News Today NAMS News Today IDYA News Today CNTA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CAPR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
